FabriceAndre

Head of Research Division of @GustaveRoussy , @myesmo President

[Daniyal Jafree @daniyal_jafree]

Check out our Opinion paper in @Nature, where we write about:

i) The decline in physician-scientist numbers worldwide
ii) Why this might be, based on our own data and others’
iii) Steps to reverse the decline

https://t.co/ugfP0LfwUQ

@rezamotallebov @CharlesSwanton @bealelab

[ESMO - Eur. Oncology @myESMO]

ESMO's new Clinical Trials Funding initiative supports independent academic pragmatic clinical trials to improve #CancerCare and patient outcomes. Open to academic institutions, hospitals, research groups.
Application deadline: 1 November 2026
https://t.co/CX9AUB6xNX

[FabriceAndre @FAndreMD]

.@esmo_iotech publishes innovations in immuno-oncology. high quality papers under the leadership of @LoiSher and @HaanenJohn

[Sherene Loi, MD @LoiSher]

🚩Can an mRNA vaccine make “cold” tumours more responsive to immunotherapy 🌶️?

A recent @Nature study suggests mRNA vaccination may activate systemic innate immunity & potentially sensitise tumours to checkpoint blockade.

The clinical data need prospective validation, but the biological concept is compelling.

The Authors discuss the implications in an @esmo_iotech commentary. 🙏@adam_grippin @StevenLin_MDPhD

Nature article linked: https://t.co/BE5zV4EEDm
IOTECH commentary: https://t.co/wmplUX63yk

@myESMO @esmo_iotech #CancerImmunotherapy #mRNA #ImmunoOncology #ESMO #ESMOIOTECH

[Toni Choueiri, MD @DrChoueiri]

I enjoyed going through this paper by @FerMosele and @GustaveRoussy team. It outlines a roadmap for the future of ADCs from soup to nuts. It was just published in @NatureMedicine —a must read for everyone with @FIFAWorldCup ⚽️ withdrawal!

Link: https://t.co/t4mXf4Ajn7

[Élysée @Elysee]

EN DIRECT | Cérémonie en hommage aux victimes de l’attentat du 14 juillet 2016 à Nice. https://t.co/tS1bsGtePJ

[Nice-Matin @Nice_Matin]

Voici la une de Nice-Matin de ce mardi 14 juillet 2026.

[Myriam Chalabi @MyriamChalabi]

Wow! Not 1️⃣, not 2️⃣, but 3️⃣‼️@Nature papers concomitantly published during #ESMO25 @myESMO
@LoiSher @adam_grippin @MDAndersonNews @PeterMacCC @NKI_nl @DrChoueiri @VanAllenLab @FAndreMD congrats to all authors and 🙏 for making this very unique session happen also @Nature ! 👇

[ESMO - Eur. Oncology @myESMO]

📣 ESMOImmuno25: Aurélien Marabelle, Scientific Co-Chair, invites you to present your research to an international audience of top-tier scientists, clinicians, and industry experts.
⏰ Deadline: 30 September 2025

🔗 https://t.co/4lEGB3IHHI

[ESMO - Eur. Oncology @myESMO]

📣 Join us in Hong Kong for a chance to contribute to oncology drug development in Asia Pacific!
⏰ Late registration deadline: 18 June

🔗 https://t.co/QW6AsMpvaj

@herbloong @TonyMok9 @DrBenTran @AyaHelali

[ASCO @ASCO]

At #ASCO25, the Joint Session between ASCO and @myESMO will discuss emerging trends & the implications of integrating biomarker testing into clinical care. #ASCODailyNews has more on this with: @ASCOPres @BenWestphalen @FAndreMD @DrBonillaOnc @jrgralow: https://t.co/TWKPJxWwx1

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

#ESMOBreast25 is next month. Love this "digestible" breast only meeting with the benefits of extra interaction with all of our international colleagues.

Registration: https://t.co/9gfHiK6ziD

Program: https://t.co/pQU1jWmshS

#bcsm @myESMO @curijoey @FAndreMD

[ESMO - Eur. Oncology @myESMO]

📢 #ESMOFellowship applications are now open!
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch or #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 https://t.co/isju2i7VMO

@E_de_Azambuja @TeresaSAmaral

[FabriceAndre @FAndreMD]

It was very sad to learn that M Schneider passed away. Maurice created @myESMO in 1975 together with G Mathe, in @VilledeNice
50 years later, @myESMO includes almost 45k members around the 🌍, trains all generations of doctors and transforms practice of oncology w its frameworks

[ESMO - Eur. Oncology @myESMO]

ESMO pays tribute to Dr Maurice Schneider who dedicated his life to advancing oncology. His efforts were instrumental in paving the way for future generations of medical oncology professionals across Europe.

[ESMO - Eur. Oncology @myESMO]

📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines

🔗https://t.co/Xut0qRrS8h

[ESMO - Eur. Oncology @myESMO]

👉 Share your findings with regional and international experts in #cancer #drugdevelopment.

⏰ You still have 3 weeks to submit your abstract to #ESMOTATAsia25, a new platform to improve cancer care in the region

Submit now:
🔗 https://t.co/jlKrdrtnN7

[Myriam Chalabi @MyriamChalabi]

Abstract submission now open for #ESMO25 in #BERLIN! We have a fantastic educational programme in place, and now it's time for the scientific programme.
Looking forward to your abstracts!
Deadline: May13th https://t.co/ne3eAUfb7Y @DrChoueiri @myESMO @DrChoueiri @FAndreMD

[ESMO - Eur. Oncology @myESMO]

📣 Join us for an insightful ESMO Webinar on Advanced Urothelial Cancer!
👩‍⚕️Our expert panel will discuss 1st & 2nd line therapies, toxicity management & more. Live Q&A included.

👉Register now!
#UrothelialCancer

🔗https://t.co/TjQLgO6jAV

[ESMO - Eur. Oncology @myESMO]

📣 ESMO #ClinicalPracticeGuideline eUpdate on #OesophagealCancer: in resectable, locally advanced oesophageal adenocarcinoma or OGJ pre- & post-operative #chemotherapy is associated with improved survival vs #Neoadjuvant #Chemoradiotherapy.

🔗 https://t.co/2uyY687G7J

[Abeid Athman (Omar). @bin_abeid]

Opening session of #ESMOAFrica2025 by the @myESMO president @FAndreMD with the amazing audience from all over Africa. @OncoAlert @curijoey @E_de_Azambuja

[ESMO - Eur. Oncology @myESMO]

Get the latest in early clinical trials at ESMO TAT 2025, from bispecific antibodies for IO, cell therapies in solid tumours (CART, NK cells, modified TCRs, TIL therapy) to MAPkinase pathway and associated targets (KRAS G12C, MAP2K4, combos). Register now!